FT - Activist investor TCI calls for VW pay overhaul

Europe’s most aggressive activist investor has called for a radical overhaul of executive pay at Volkswagen, arguing “corporate excess on an epic scale” encouraged risk taking that contributed to the diesel emissions scandal.


TCI, the hedge fund run by Sir Chris Hohn, has built up a €1.2bn stake in VW and has written to the company’s management and supervisory boards demanding reform of executive pay, write Miles Johnson in London and Patrick McGee in Frankfurt.

The German carmaker is reeling from the diesel emissions fraud, the worst crisis in its 78 year history, in which it admitted installing defeat devices in up to 11m diesel powered vehicles that served to understate emissions of harmful nitrogen oxides in official tests.

VW reported a €1.6bn net loss for 2015 — its worst ever result, mainly because of costs stemming from the scandal. VW was also criticised by investors after it emerged that members of its management board secured bonuses for last year. Although some remuneration was withheld, the board members were paid €63.2m in total.

“The dirty secret of Volkswagen group is that for years management has been richly rewarded with massive compensation despite presiding over a productivity and profit collapse,” Sir Chris Hohn told the Financial Times.

“We believe that this excessive top management compensation . . . has encouraged aggressive management behaviour contributing to the diesel emission scandal.”

VW had no immediate comment on TCI, which has amassed a 2 per cent stake in the company’s preference stock.

>>> U.S. April Nonfarm Payrolls Rose 160k; Unemp. Rate at 5%

U.S. April Nonfarm Payrolls Rose 160k; Unemp. Rate at 5%
Nonfarm payrolls forecast est. 200k, range 160k-315k from 92 economists surveyed
• Nonfarm payrolls, net revisions, subtracted 19k from prior two months
• Participation rate 62.8% vs prior 63%
• Avg. hourly earnings m/m 0.3%, est. 0.3%, prior 0.2%
• Y/y 2.5%, prior 2.3% est. 2.4%
• Nonfarm private payrolls rose 171k vs prior 184k; est. 195k, range 150k-242k from 45 economists surveyed
• Manufacturing payrolls rose 4k after falling 29k in the prior month; economists estimated -5k, range -20k to 22k from 26 economists surveyed
• Unemployment rate 5% vs prior 5.0%; est. 4.9%, range 4.8%-5.1% from 86 economists surveyed
• Underemployment rate 9.7% vs prior 9.8%
• Change in household employment fell 316k vs prior up 246k

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: GV +20.8%, SYN +18.8%, CTRL+14.9%, YELP +13.7%, RATE +13.6%, HLF +12.8%, PACD +12.3%, SPPI +10.6%,UBNT +10.2%, MDR +8.6%, GSAT +8.2%, ACAD +7.2%, PTCT +6.8%, ATHX+6.8%, TRQ +6.7%, SWIR +6.6%, POST +6.5%, ATVI +6.3%, CLNE +5.5%, MTZ+5.4%, INAP +5%, NBIX +4.5%, HTGC +4.4%, BLDR +4.1%, AL +3.8%, ANET+3.8%, ATW +3.8%, TEAM +3.7%, MELI +3.4%, DV +3.2%, BATS +3.2%, VRNG+2.5%, WYNN +2.1%, UEIC +1.9%, CLVS +1.9%, WING +1.9%, WEB +1.8%, EXC+1.8%, MDVN +1.6%, EGY +1.6%, EVDY +1.5%, MAIN +1.4%, SAAS +1.1%, AHT+1%, RRMS +0.9%, EGN +0.9%

M&A news: RATE +13.6% (to acquire the business of NextAdvisor for ~$76.3 mln in cash and ~$3.00 mln in time-based vesting restricted stock units), APD+2.3% (confirms deal to sell the Performance Materials Division of its Materials Technologies segment to Evonik Industries for $3.8 bln)

Select metals/mining stocks trading higher: GOLD +1.7%, ABX +1.6%, GFI+0.7%, VALE +0.6%, GDX +0.5%

Other news: CRME +31.7% (Cardiome Pharma & Allergan (AGN) sign exclusive license agreement to commercialize Xydalba in France, the UK, Germany, Belgium, Nordic nations, and certain other European nations along with Canada and the middle east, additional terms undisclosed ), SPHS +21.1% (Sophiris Bio will present 'positive' data from its Phase 3 study of topsalysin as a treatment for the symptoms of benign prostatic hyperplasia at the American Urological Association Annual Meeting on May 7)

Analyst comments: CTRV +3.1% (initiated with a Buy at Maxim Group; tgt $4),ARIA +2.5% (upgraded to Outperform from Market Perform at Cowen), MDVN+1.6% (upgraded to Buy from Neutral at Citigroup)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: ENDP -30.3%, GST -26.3%,IMPV -18.8%, UNXL -17.4%, SQ -16.6%, BSQR -14.1%, FEYE -8.6%, (Chairman and CEO David DeWalt will assume executive chairman role; President Kevin Mandia will replace as CEO ), GPRO -7.7%, DATA -5.8%, CPA -5.8%, FLR-5.6%, CRC -4.8%, GDEN -4.2%, CERN -4.1%, OLED -3.7%, CYBR -3.3%, LOCO-3.3%, TRUE -3.2%, EFC -3.2%, PMT -2.3%, MT -2.1%, CTSH -2.1%, HRTX-1.9%, FPRX -1.9%, PETX -1.8%, LNG -1.7%, SPWR -1.5%, ICPT -1.5%, EGAN-1.4%, PDCE -1.4%, DEPO -1.3%, MDRX -1.2%, GERN -1.1%, LIND -0.8%

Select Chinese ADR's showing continued weakness: VNET -4.9%, AMCN -2.1%,YY -1.7%, YNDX -1.6%

Select oil/gas related names showing early weakness: SDRL -4.9%, CHK -2.8%,SSL -2.4%, STO -1.9%, RDS.A -1.4%, BP -1.3%, MRO -0.8%

Other news: KMPH -45.8% (the Anesthetic and Analgesic Drug Products Advisory Committee determined by a vote of 16 to 4 in that Apadaz should be approved for its proposed indication and voted 18 to 2 against inclusion of abuse deterrent labeling for the product), ARP -15.9% (suspends common unit and Class C preferred distributions, due to continued lower commodity price environment), PLG -8.8% (announces $33 mln bought-deal financing of 11 mln shares priced at $3.00/share with a syndicate of underwriters ), BANC -7% (announces 5.25 mln share underwritten public offering of common stock ),JCP -5.4% (NYPost detailed an internal memo on cost cutting measures amid recent sales decline), SO -4% (prices offering of 18.3 mln shares of common stock for gross proceeds of ~900 mln), VRX -3.3% ( announces formation of a new patient access & pricing committee responsible for pricing the co's drugs, chaired by CEO Joseph Papa), WBA -2.4% ( commences 15 mln common stock offering by selling stockholders), BHP -1.4% (provides Samarco update; Federal Court of Appeal in Brazil ratifies the agreement announced on Mar 2)

Analyst comments: ZTS -3.4% (downgraded to Sell from Neutral at Goldman),BNFT -1.6% (downgraded to Market Perform from Outperform at William Blair)